Gmax Biopharm, a Hangzhou GPCR antibody company, has dosed the first patient in a Phase Ib trial aimed at treating pulmonary arterial hypertension (PAH). The company says GMA301, which is the first antibody to target PAH, is a humanized mAb (IgG4) intended to inhibit endothelin receptor type A (ETa). Gmax said CMA301 demonstrated a half-life of 500-570 hours in its Phase Ia trial, which would permit once-per-month administration. The Phase Ib trial will be a multi-center test conducted in China and the US . More details.... Share this with colleagues: // //